{"name": "Mnemosyne Pharmaceuticals",
 "permalink": "mnemosyne-pharmaceuticals",
 "crunchbase_url": "http://www.crunchbase.com/company/mnemosyne-pharmaceuticals",
 "homepage_url": "http://mnemosynepharma.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "info@mnemosynepharma.com",
 "phone_number": "401.632.0383",
 "description": "",
 "created_at": "Fri Feb 17 02:17:12 UTC 2012",
 "updated_at": "Fri Feb 17 02:19:48 UTC 2012",
 "overview": "\u003Cp\u003EMnemosyne Pharmaceuticals, Inc. is developing an innovative drug discovery platform that will address medical needs in several segments of the mental health market.\u003C/p\u003E\n\n\u003Cp\u003EMnemosyne was founded in 2010 with seed funding from Slater Technology Fund and private investors. Recently, Mnemosyne closed on a Series A round totaling $5.4M. Mnemosyne is using these funds to develop a new class of small molecule drugs that modulate the activity of different subtypes of the NMDA receptor.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       81],
      "assets/images/resized/0017/4621/174621v1-max-150x150.png"],
     [[216,
       117],
      "assets/images/resized/0017/4621/174621v1-max-250x250.png"],
     [[216,
       117],
      "assets/images/resized/0017/4621/174621v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "CEO",
    "person":
     {"first_name": "Kollol",
      "last_name": "Pal",
      "permalink": "kollol-pal",
      "image": null}},
   {"is_past": false,
    "title": "Chief Scientific Officer",
    "person":
     {"first_name": "Frank",
      "last_name": "S. Menniti",
      "permalink": "frank-s-menniti",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$5.4M",
 "funding_rounds":
  [{"round_code": "a",
    "source_url": "http://www.masshightech.com/stories/2012/02/13/daily33-Mnemosyne-Pharmaceuticals-lands-54M-in-Series-A-round.html",
    "source_description": "Mnemosyne Pharmaceuticals lands $5.4M in Series A round",
    "raised_amount": 5400000.0,
    "raised_currency_code": "USD",
    "funded_year": 2012,
    "funded_month": 2,
    "funded_day": 16,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Access BridgeGap Ventures",
         "permalink": "access-bridgegap-ventures",
         "image": null},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Slater Technology Fund",
         "permalink": "slater-technology-fund",
         "image":
          {"available_sizes":
            [[[150,
               20],
              "assets/images/resized/0003/0384/30384v2-max-150x150.png"],
             [[250,
               33],
              "assets/images/resized/0003/0384/30384v2-max-250x250.png"],
             [[300,
               40],
              "assets/images/resized/0003/0384/30384v2-max-450x450.png"]],
           "attribution": null}},
       "person": null}]}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "One Davol Square",
    "address2": "Suite 200",
    "zip_code": "02903",
    "city": "Providence",
    "state_code": "RI",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [{"available_sizes":
     [[[150,
        114],
       "assets/images/resized/0017/4622/174622v1-max-150x150.png"],
      [[250,
        190],
       "assets/images/resized/0017/4622/174622v1-max-250x250.png"],
      [[450,
        342],
       "assets/images/resized/0017/4622/174622v1-max-450x450.png"]],
    "attribution": null}],
 "external_links":
  []}